A quick peek into the report
Hematologic Malignancies Testing Market Report Coverage
|
Hematologic Malignancies Testing Market |
|||
|
Base Year |
2023 |
Market Size in 2023 |
$3,546.3 Million |
|
Forecast Period |
2024-2033 |
Value Projection and Estimation by 2033 |
$13,509.5 Million |
|
CAGR During Forecast Period |
14.09% |
Number of Pages |
258 |
| Number of Tables | 199 |
Number of Figures |
71 |
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Based on product, the hematologic malignancies testing market service segment players leading the market captured around 58.36% of the market's presence as of 2023. Kits, on the other hand, accounted for approximately 41.64% of the market presence in 2023, respectively.
Source: BIS Research Analysis
Some prominent names established in this market are:
• Abbott Laboratories
• Adaptive Biotechnologies
• ARUP Laboratories
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• ICON plc
• Illumina, Inc.
• Invitae Corporation
• Invivoscribe Inc.
• Laboratory Corporation of America Holdings
• NeoGenomics Laboratories
• OHSU’s Knight Diagnostic Laboratories
• QIAGEN N.V.
• Quest Diagnostics
• Sysmex Corporation
• Tempus Labs, Inc
• Bio-Techne
• DiaSorin S.p.A
• Foundation Medicine, Inc.
• Thermo Fisher Scientific, Inc.
• ELITech Group
• Vela Diagnostics
• Amoy Diagnostics Co., Ltd.
• Integrated DNA Technologies, Inc.
Global Hematologic Malignancies Testing Market Industry Overview
The global hematologic malignancies testing market was valued at $3,546.3 million in 2023 and is expected to reach $13,509.5 million by 2033, growing at a CAGR of 14.09% during the forecast period 2024-2033. The hematologic malignancies testing market focuses on diagnostic tools and technologies for detecting and monitoring blood cancers such as leukemia, lymphoma, and myeloma. With the growing incidence of these cancers and advancements in diagnostic methods, the market is rapidly expanding. Key technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, and immunohistochemistry. These tools are crucial for accurate diagnosis, prognosis, and treatment planning.
The growth of the hematologic malignancies testing market is driven by several factors, such as the rising burden of hematological cancer, growing research publications, and clinical trials in hematologic malignancies testing, leading to increased demand for hematologic malignancies tests and products. Additionally, increased funding and community support for early detection and treatment create a demand for hematological malignancy testing kits and services, and continuous advancements in hematologic malignancy have led to the development of more effective and innovative tests and kits. Moreover, the expanding availability of these supplements through various distribution channels, including online platforms and retail stores, has further facilitated market expansion and accessibility to consumers worldwide.
Market Introduction
The hematological malignancies testing market focuses on diagnostic tools and technologies used to identify and monitor cancers of the blood, including leukemia, lymphoma, and myeloma. This market is growing significantly, driven by the rising incidence of these cancers, technological advancements in diagnostics, and a focus on early detection and personalized medicine. The rising prevalence of hematologic malignancies globally highlights substantial growth potential in the healthcare sector. GLOBOCAN projects a 56.37% increase in these cancers by 2050 compared to 2022. As these diseases become more widespread across various regions, there is expected to be a growing need for advanced diagnostic tools, effective therapeutic interventions, and comprehensive supportive care services to meet the increasing healthcare demands.
The growing emphasis on personalized oncology and targeted therapies for hematological cancer treatment has fuelled demand for companion diagnostics tests on hematologic malignancies testing. Facilitation of its adoption in clinical practices by government approvals and reimbursement policies has paved the way for their integration into standard oncology care. As awareness about early cancer detection and its non-invasive diagnostic method continues to rise, the hematologic malignancies testing market is poised for further expansion and diversification in the coming years.
Industrial Impact
The growth of the hematologic malignancies testing market has not only provided relief to individuals having cancer symptoms but has also had a notable industrial impact. Manufacturers and suppliers of these products have witnessed increased demand, leading to expanded production capacities and job creation within the industry.
Market Segmentation:
Segmentation 1: by Product
• Kits
• Services
Services Segment to Dominate the Hematologic Malignancies Testing Market (by Product)
The services segment is expected to dominate the hematologic malignancies testing market by product. This is primarily due to the complexity of tests and the advanced technology required in performing the hematologic malignancies testing. The service providers not only perform the tests but also handle data analysis.
Segmentation 2: by Platform
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Flow Cytometry
• Other Platforms
Polymerase Chain Reaction (PCR) Segment to Dominate the Hematologic Malignancies Testing Market (by Platform)
The polymerase chain reaction (PCR) segment is anticipated to dominate the hematologic malignancies testing market by platform. This predominance results from its rapid turnaround times and high sensitivity and specificity, which are essential for detecting and quantifying specific genetic changes linked to various hematologic cancers.
Segmentation 3: by Disease
• Leukemia
• Lymphoma
• Multiple Myeloma
• Myeloproliferative Neoplasms
• Myelodysplastic Syndrome
Leukemia Segment to Dominate the Hematologic Malignancies Testing Market (by Diseases)
The leukemia segment is expected to dominate the hematologic malignancies testing market based on diseases. This predominance results from the high prevalence and incidence of leukemia, which elevates the demand for diagnostic testing. The complexity of leukemia, with its various subtypes requiring specific diagnostic methods, further intensifies the need for comprehensive testing.
Segmentation 4: by End User
• Specialty Clinics and Hospitals
• Diagnostic Laboratories
• Reference Laboratories
Specialty Clinics and Hospitals Segment to Dominate the Hematologic Malignancies Testing Market (by End User)
The specialty clinics and hospitals segment of the hematologic malignancies testing market by end user is expected to lead the market. This leadership stems from their integrated patient care models that ensure timely and coordinated diagnosis and treatment, which are critical for hematologic malignancies. These facilities feature advanced infrastructure to support sophisticated diagnostic tools and employ specialized personnel essential for interpreting complex test results.
Segmentation 5: by Region
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Denmark
o Rest-of-Europe
• Asia-Pacific
o Japan
o India
o China
o South Korea
o Australia
o Singapore
o Rest-of-Asia-Pacific
• Latin America
o Brazil
o Mexico
o Rest-of-Latin America
• Middle East and Africa
o K.S.A.
o U.A.E.
o South Africa
o Rest-of-Middle East and Africa
The North America region is positioned to hold a significant share of the global market for several compelling reasons. North America's growth has been driven by high rates of hematologic malignancies in the U.S. and Canada. Europe and Asia-Pacific are expected to see substantial growth, with China showing strong performance and increased adoption in Japan and India. Strategic partnerships in Latin America and other regions are tackling infrastructure challenges, thereby creating opportunities for manufacturers and service providers worldwide.
Recent Developments in the Hematologic Malignancies Testing Market
• In May 2024, Bruker Corporation acquired ELITech Group with an expectation of generating revenue of $100 million by ELITech Group from the remainder of 2024.
• In April 2024, QIAGEN N.V. announced the launch of the QIAseq Targeted RNA-seq Panel for T-cell receptors, emphasizing their critical role in the adaptive immune system's function of recognizing and eliminating abnormal cells, including cancer cells.
• In February 2024, Precipio, Inc. announced the signing of a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, primarily comprising acute healthcare systems (hospital networks), reference laboratories, and physician-owned laboratories.
• In January 2024, Illumina, Inc. announced it signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration marks the first step in developing Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to enhance understanding of disease persistence or recurrence after clinical intervention.
Demand – Drivers, Challenges, and Opportunities
Market Demand Drivers:
Rising Incidence of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Leukemia Facilitating the Demand for Hematologic Malignancy Testing Kits and Services: The increasing prevalence of hematologic malignancies globally highlights significant growth potential in the healthcare sector. GLOBOCAN projects a 56.37% rise in these cancers by 2050 compared to 2022. As these diseases become more common across various regions, there will be a critical need for advanced diagnostic tools, effective therapeutic interventions, and comprehensive supportive care services to meet the growing healthcare demands.
Market Challenges:
Challenges in Integrating NGS into Clinical Practice for Hematologic Malignancies: Integrating next-generation sequencing (NGS) into clinical diagnostics for hematologic malignancies encounters significant challenges, hindering market growth. Despite its potential to transform disease classification, risk assessment, and treatment decisions, the complexity of interpreting and applying NGS-derived molecular genetic data remains a major obstacle. The phenotypic and genetic diversity of acute and chronic myeloid malignancies requires advanced expertise and sophisticated bioinformatic tools to differentiate clinically relevant driver mutations from incidental passenger mutations.
Market Opportunities:
Leveraging AI for Enhanced Diagnostics in the Hematologic Malignancies Testing Market: Integrating artificial intelligence (AI) into the diagnosis of hematologic malignancies offers a significant business opportunity in the global hematologic malignancies testing market. Researchers at the Ohio State University Comprehensive Cancer Center have demonstrated AI's potential to accurately differentiate between two rare blood cancers, prefibrotic primary myelofibrosis (prePMF) and essential thrombocythemia (ET). This distinction is crucial for determining appropriate treatment and enrolling patients in clinical trials, a task that traditional diagnostic methods find challenging.
Analyst’s Thoughts
According to Swati Sood, Principal Analyst – BIS Research, “The growth of the hematologic malignancies testing market has been primarily driven by the rising burden of cancer, growing research publications and clinical trials, and growing adoption and demand of minimally invasive cancer detection methods.”
Hematologic Malignancies Testing Market - A Global and Regional Analysis
Focus on Product, Platform, Disease, End User, and Region - Analysis and Forecast, 2024-2033
Frequently Asked Questions
Hematologic malignancy testing includes various diagnostic procedures to detect, monitor, and manage blood and lymphatic system cancers such as leukemia, lymphoma, and myeloma. These tests are crucial for identifying the specific type of blood cancer, assessing its progression, and determining the most effective treatment plan.
Existing market players in the hematologic malignancies testing industry are adopting various new strategies to strengthen their market position. One prominent strategy has been product diversification, where companies expand their product lines to offer a wider range of tests and kits tailored to different indications of cancer. This allows them to cater to diverse consumer needs and preferences, capturing a larger share of the market. Additionally, companies are investing in research and development to innovate and improve existing formulations, incorporating new technologies to enhance the effectiveness and accuracy of their products. Another strategy involves strategic partnerships or collaborations with healthcare professionals, wellness experts, or influencers to endorse their products and increase brand credibility and visibility among different companies for the co-development of products.
The following are the USPs of this report:
• Market regulations and a list of key trends in the hematologic malignancies testing market
• Supply chain analysis and pricing analysis
• A competitive index of the market specific to the unmet needs and innovations of the key players
• Key challenges faced by manufacturers
• Market dynamic analysis of the drivers, opportunities, and challenges in the market
• Competitive benchmarking of key players for each product type
Manufacturers and entrepreneurs in the oncology field can benefit from the insights to better understand available products. Pharmaceutical companies and manufacturers involved in hematologic malignancy testing can use the report to assess market trends, identify opportunities for product development, and refine marketing strategies. Retailers, including pharmacies, drug stores, and online retailers, can gain insights into consumer preferences and market dynamics to optimize their product offerings and distribution channels. Investors and financial analysts can leverage the report to evaluate the market's growth potential, assess investment opportunities, and make informed decisions.